Thermo Fisher Scientific(US:TMO) ZACKS·2025-10-17 14:16Core Viewpoint - Thermo Fisher Scientific (TMO) is expected to report quarterly earnings of $5.50 per share, a 4.2% increase year-over-year, with revenues projected at $10.9 billion, reflecting a 2.8% year-over-year increase [1]. Earnings Estimates - The consensus EPS estimate has been revised down by 0.5% in the last 30 days, indicating a reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Forecasts - Analysts forecast 'Revenues- Laboratory Products and Biopharma Services' to reach $5.93 billion, a year-over-year increase of 3.2% [5]. - The estimate for 'Revenues- Specialty Diagnostics' is $1.16 billion, also reflecting a 3.2% year-over-year increase [5]. - 'Revenues- Life Sciences Solutions' are expected to be $2.47 billion, indicating a 3.6% year-over-year increase [5]. - 'Revenues- Analytical Instruments' are projected at $1.80 billion, showing a slight decline of 0.3% year-over-year [6]. Geographic Revenue Projections - North America revenues are expected to reach $5.74 billion, a 2.7% increase from the prior year [6]. - Asia-Pacific revenues are projected at $1.99 billion, reflecting a 3.6% year-over-year increase [6]. - Revenues from Europe are estimated to be $2.77 billion, indicating a 3.1% year-over-year increase [7]. - Revenues from other regions are expected to be $379.01 million, showing a decline of 4.5% year-over-year [7]. Stock Performance - Over the past month, Thermo Fisher shares have increased by 11.6%, outperforming the Zacks S&P 500 composite, which saw a 0.7% change [7]. - Based on its Zacks Rank 4 (Sell), TMO is expected to underperform the overall market in the upcoming period [7].